argenx is a high-quality biotech with 52% revenue growth, 32% margins, a wide moat and a 9/9 Piotroski score; the main hesitation is a 26.8x forward P/E and a reward-to-risk of 1.33 that has not yet produced a breakout.
Thesis pillars
- High Quality Wide Moat→Stable
- Hypergrowth Revenue Expansion→Stable
- Premium Valuation Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026
argenx SE (ARGX) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $900.72. At $931.38 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $900.72 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... Read more
Wait for pullback to $900.72. At $931.38 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $900.72 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.21, quality 9.2/10, growth 10.0/10). Score 7.1/10, high confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 112d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — argenx SE
Latest news
- NEWS Best Biotech Stocks to Buy Now as AI Stocks Tank: ARGX - Yahoo Finance — Yahoo Finance Nov 4, 2026 neutral
- NEWS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX - FinancialContent — FinancialContent Nov 3, 2026 negative
- NEWS Argenx SE : Jefferies gives a Buy rating - marketscreener.com — marketscreener.com Oct 28, 2026 positive
- NEWS Citi Initiates Upside Catalyst Watch on Argenx (ARGX) Ahead of P - GuruFocus — GuruFocus Oct 21, 2026 positive
- NEWS argenx Stock Gets A Lift From Positive Phase 3 Trial Results - Simply Wall Street — Simply Wall Street Oct 21, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:29:00Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $900.72. At $931.38 the A.R:R is 0.7:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $900.72 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.21, quality 9.2/10, growth 10.0/10). Target $1032.61 (+10.9%), stop $843.92 (−10.4%), A.R:R 0.7:1. Score 7.1/10, high confidence.
Take-profit target: $1032.61 (+10.9% upside). Target $1032.61 (+10.9%), stop $843.92 (−10.4%), A.R:R 0.7:1. Stop-loss: $843.92.
argenx SE trades at a P/E of 32.3 (forward 28.0). TrendMatrix value score: 4.8/10. Verdict: Buy (Wait for Entry).
26 analysts rate ARGX, with a consensus score of 4.2/5. 23 analysts publish price targets averaging $1147.
What does argenx SE do?argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in...
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.